Dendritic α,ε-poly(L-lysine)s as delivery agents for antisense oligonucleotides

被引:43
作者
Eom, Khee Dong
Park, Sun Mi
Tran, Huu Dung
Kim, Myong Soo
Yu, Ri Na
Yoo, Hoon
机构
[1] Chosun Univ, Dept Pharmacol & Dent Therapeut, Coll Dent, Kwangju 501759, South Korea
[2] Nannorm Inc, Seoul 136130, South Korea
[3] Univ Ulsan, Dept Food Sci & Nutr, Ulsan 680749, South Korea
基金
新加坡国家研究基金会;
关键词
antisense oligonucleotide; delivery; dendritic alpha; epsilon-poly(L-lysine);
D O I
10.1007/s11095-006-9231-y
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
`Purpose. To evaluate the potential use of dendritic alpha,epsilon-poly(L-lysine)s ( DPL) for the efficient cellular delivery of antisense oligonucleotides. Methods. A series of dendritic alpha, epsilon-polylysines of various generations were prepared. Their physical properties and the ability to form complex with oligonucleotide were investigated by polyacrylamide gel electrophoresis, capillary zone electrophoresis (CZE), agarose gel electrophoresis, fluorescence titration and atomic force microscopy (AFM). The efficiency to deliver oligonucleotide to HeLa cells, stably transfected with plasmid pLuc/ 705, was evaluated by using antisense splicing correction assay and confocal microscopy. Results. DPLs formed the complexes with antisense oligonucleotide with modest cytotoxicity. The charge ratio of oligonucleotide to DPL and the size (generation) of DPLs were all critical variables for the antisense effect. Compared to low generation DPLs, high generation DPLs were more effective in delivering oligonucleotide into cells. Conclusions. High generation DPL-oligonucleotide complexes were moderately effective for delivery antisense oligonucleotide. The complex formation provides a promise for in vivo therapeutic application of DPLs or their derivatives in the delivery of gene or oligonucleotide.
引用
收藏
页码:1581 / 1589
页数:9
相关论文
共 29 条
[1]
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis [J].
Akinc, A ;
Thomas, M ;
Klibanov, AM ;
Langer, R .
JOURNAL OF GENE MEDICINE, 2005, 7 (05) :657-663
[2]
Baker D. R., 1995, CAPILLARY ELECTROPHO
[3]
Antisense oligonucleotides: Is the glass half full or half empty? [J].
Bennett, CF .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (01) :9-19
[4]
Molecular mechanisms of action of antisense drugs [J].
Crooke, ST .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :31-44
[5]
Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery [J].
DeLong, R ;
Stephenson, K ;
Loftus, T ;
Fisher, M ;
Alahari, S ;
Nolting, A ;
Juliano, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (06) :762-764
[6]
EOM KD, 2003, P 18 AM PEPT S, P924
[7]
Eom KD, 2006, J NANOSCI NANOTECHNO, V6, P3532, DOI 10.1166/jnn.2006.050
[8]
Improved cationic lipid formulations for in vivo gene therapy [J].
Felgner, PL ;
Tsai, YJ ;
Sukhu, L ;
Wheeler, CJ ;
Manthorpe, M ;
Marshall, J ;
Cheng, SH .
DNA VACCINES: A NEW ERA IN VACCINOLOGY, 1995, 772 :126-139
[9]
Nucleic acid therapeutics: State of the art and future prospects [J].
Gewirtz, AM ;
Sokol, DL ;
Ratajczak, MZ .
BLOOD, 1998, 92 (03) :712-736
[10]
A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides [J].
Hussain, M ;
Shchepinov, MS ;
Sohail, M ;
Benter, IF ;
Hollins, AJ ;
Southern, EM ;
Akhtar, S .
JOURNAL OF CONTROLLED RELEASE, 2004, 99 (01) :139-155